Atypical Chemokine Receptors in Cardiovascular Disease.


Journal

Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 5 2 2019
medline: 13 9 2019
entrez: 5 2 2019
Statut: ppublish

Résumé

Inflammation has been well recognized as one of the main drivers of atherosclerosis development and therefore cardiovascular diseases (CVDs). It has been shown that several chemokines, small 8 to 12 kDa cytokines with chemotactic properties, play a crucial role in the pathophysiology of atherosclerosis. Chemokines classically mediate their effects by binding to G-protein-coupled receptors called chemokine receptors. In addition, chemokines can also bind to atypical chemokine receptors (ACKRs). ACKRs fail to induce G-protein-dependent signalling pathways and thus subsequent cellular response, but instead are able to internalize, scavenge or transport chemokines. In this review, we will give an overview of the current knowledge about the involvement of ACKR1-4 in CVDs and especially in atherosclerosis development. In the recent years, several studies have highlighted the importance of ACKRs in CVDs, although there are still several controversies and unexplored aspects that have to be further elucidated. A better understanding of the precise role of these atypical receptors may pave the way towards novel and improved therapeutic strategies.

Identifiants

pubmed: 30716778
doi: 10.1055/s-0038-1676988
doi:

Substances chimiques

ACKR1 protein, human 0
ACKR2 protein, human 0
ACKR3 protein, human 0
ACKR4 protein, human 0
Chemokines 0
Cytokines 0
Duffy Blood-Group System 0
Lipids 0
Receptors, CCR 0
Receptors, CXCR 0
Receptors, Cell Surface 0
Receptors, Chemokine 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

534-541

Informations de copyright

Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Selin Gencer (S)

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.

Emiel P C van der Vorst (EPC)

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.

Maria Aslani (M)

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.

Christian Weber (C)

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.

Yvonne Döring (Y)

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

Johan Duchene (J)

Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH